B3	 (Amended) A peptide comprising a sequence of 14-50 amino acids characterised in that it contains a peptide turn comprising at least one citrulline residue, and it contains less than 12 amino acids between two cysteine residues, with said citrulline residue being one of the amino acids between said cysteine residues and said peptide is specifically recognised by rheumatoid arthritis autoimmune antibodies from patients suffering from rheumatoid arthritis. 	
BH	8. (Twice Amended) A peptide according to claim 1 characterised in that the amino acids flanking the citrulline residue do not interact with the citrulline side chain.	
B.5	 12. (Twice Amended) A diagnostic kit for use in detecting rheumatoid arthritis, said kit comprising at least one peptide according to claim 1, with said peptide or antibody optionally bound to a solid support. 13. (Twice Amended) A diagnostic kit according to claim 12, said kit comprising a range of peptides according to claim 1, optionally in combination with antigens that constitute immunogenic determinants for other auto-immune diseases, wherein said peptides are attached to specific locations on a solid substrate. 	
Blo	15. (Twice Amended) A diagnostic kit according to claim 13 further comprising certain peptides that are not specific recognised by antibodies specific for rheumatoid arthritis and that are not attached to a solid support but are provided in the binding solution to be used as competitors and/or to block other antibodies that are present in sera from patients with autoimmune disease other than rheumatoid arthritis, thereby decreasing or eliminating possible cross-reaction and/or a-specific binding.	
B7	18. (Twice Amended) An immunotoxin molecule comprising a cell recognition molecule being a peptide of claim 1, covalently bound to a toxin molecule or active fragment thereof.	
B8	20. (Twice Amended) A diagnosticum for rheumatoid arthritis comprising a peptide according to claim 1 or an immunotoxin molecule according to claim 18.	